

Dr. Jonathan Mizrahi
Medical Oncologist
Dr. Jonathan Mizrahi is a medical oncologist with Ochsner Health in New Orleans, Louisiana.
Podcasts
Vascular & IR # 647May 21, 2026Optimizing Liver Cancer Treatment Through Collaboration

In treating hepatocellular carcinoma (HCC), the hardest question often isn’t which treatment to use, it’s who should lead, when to transition care, and how to keep every specialty aligned. In this App Exclusive episode of the BackTable Podcast, host Dr. Jon Mizrahi is joined by interventional radiologist Dr. Juan Gimenez and transplant surgeon Dr. Ari Cohen, to discuss the structure and evolution of Ochsner Health’s multidisciplinary tumor board. Through real-world cases, they illustrate how IR, hepatology, and transplant surgery collaborate to tailor treatment plans, coordinate transitions of care, and navigate follow-up challenges for complex HCC patients.
29m
Tumor Board # 59May 12, 2026Evolving Treatment Paradigms in Hepatocellular Carcinoma: What's on the Horizon?

With new systemic and liver-directed approaches under investigation, which targets and treatment strategies are most likely to shape HCC care? In this final episode of the BackTable 2026 HCC Creator Weekend™, Drs. Lingling Du, A. Craig Lockhart, and Jon Mizrahi focus on the future of hepatocellular carcinoma beyond established PD-1/CTLA-4 regimens.
25m
Tumor Board # 58May 5, 2026Advanced Hepatocellular Carcinoma: Navigating Second-Line Therapy Options

When first-line treatment for advanced hepatocellular carcinoma (HCC) fails and the disease progresses, what options are available for second-line therapy? In this episode of the BackTable 2026 HCC Creator Weekend™, Drs. Lingling Du, A. Craig Lockhart, and Jon Mizrahi explore the uncertain landscape of second-line treatment after first-line immunotherapy, such as atezolizumab and bevacizumab or the STRIDE regimen, including practical considerations for choosing which second-line therapy to use.
26m
Tumor Board # 57Apr 28, 2026First-Line Therapy for Advanced Hepatocellular Carcinoma: Decisions in the Real World

Learn how a “watershed” clinical trial in 2020 completely overturned a decade of standard care for liver cancer. In this inaugural episode of the BackTable 2026 HCC Creator Weekend™ , medical oncologists Dr. John Rahi, Dr. Craig Lockhart, and Dr. Lingling Du review the evolution of first-line systemic therapy for hepatocellular carcinoma (HCC), highlighting immune checkpoint inhibitors as a major change from the TKI era.
29m
Tumor Board # 44Jan 20, 2026ESMO Update: Advances in Upper GI Malignancies

The FLOT regimen is the standard-of-care for upper gastroesophageal malignancies, but what if there were other drug combinations or perioperative strategies that could further improve outcomes? In Part II of our ESMO 2025 recap, medical oncologists Dr. Jun Gong and Dr. Jonathan Mizrahi cover emerging studies and treatments in gastroesophageal cancers.
16m
Tumor Board # 43Jan 13, 2026ESMO Update: Trial Results & New Therapies in Colorectal Cancer

Get caught up on the cutting edge colorectal cancer trial data from ESMO 2025 with this 30-minute BackTable Tumor Board recap! Featuring medical oncologists Dr. Jonothan Mizrahi and Dr. Jun Gong.
30m
Tumor Board # 42Jan 6, 2026Neoadjuvant Therapy in Resectable Pancreatic Cancer

For the small subset of pancreatic cancer patients whose cancer is detected early and remains localized, there are now opportunities to offer treatment and improve outcomes. In this episode of the BackTable Tumor Board Podcast, Ochsner medical oncologist Dr. Jonathan Mizrahi and MD Anderson surgical oncologist Dr. Rebecca Snyder discuss the contemporary management of localized pancreatic cancer.
43m
Tumor Board # 41Dec 30, 2025Advanced Pancreatic Cancer: Systemic Therapy Strategies

Metastatic pancreatic cancer is no longer a ‘one size fits all’ diagnosis. In this episode of the BackTable Tumor Board Podcast, medical oncologist Dr. Jon Mizrahi and Dr. Shubham Pant, a professor of GI Medical Oncology at MD Anderson Cancer Center, discuss the evolving landscape of systemic therapy for advanced pancreatic cancer.
41m
Vascular & IR # 513Jan 31, 2025Combination Therapy & Clinical Trials for Advanced HCC: What They Really Mean

In the past five years, the use of immunotherapeutic agents for advanced cancers has emerged as a promising alternative to tyrosine kinase inhibitors and chemotherapy, making it an exciting time to be practicing oncology. In this episode, Dr. Tyler Sandow interviews oncology experts about the landscape of advanced hepatocellular carcinoma (HCC) and the current state of immunotherapy treatments. He is joined by medical oncologists Dr. Jonathan Mizrah, Dr. Lingling Du, and Dr. Adam Burgoyne, as well as interventional oncologist Dr. Zachary Berman.
46m
Tumor Board # 3Jan 17, 2025Combination Therapy & Clinical Trials for Advanced HCC: What They Really Mean

In the past five years, the use of immunotherapeutic agents for advanced cancers has emerged as a promising alternative to tyrosine kinase inhibitors and chemotherapy, making it an exciting time to be practicing oncology. In this episode, Dr. Tyler Sandow interviews oncology experts about the landscape of advanced hepatocellular carcinoma (HCC) and the current state of immunotherapy treatments. He is joined by medical oncologists Dr. Jonathan Mizrah, Dr. Lingling Du, and Dr. Adam Burgoyne, as well as interventional oncologist Dr. Zachary Berman.
46m
Tumor Board # 1Jan 17, 2025Multidisciplinary HCC Care: Improving the Patient Experience with Combined Clinics

Welcome to the first episode of BackTable Tumor Board, and our first recording session at our new in-person studio! Guest host Dr. Tyler Sandow (interventional radiologist) leads a multidisciplinary discussion about patient care coordination in hepatocellular carcinoma (HCC) diagnosis and treatment, with insights from his colleagues at Ochsner Health– Dr. Steven Young (hepatologist), Dr. Jonathan Mizrahi (medical oncologist), and Deondra Bonds-Adams (patient navigator).
43m
Vascular & IR # 509Jan 17, 2025Multidisciplinary HCC Care: Improving the Patient Experience with Combined Clinics

Welcome to the first episode of BackTable Tumor Board, and our first recording session at our new in-person studio! Guest host Dr. Tyler Sandow (interventional radiologist) leads a multidisciplinary discussion about patient care coordination in hepatocellular carcinoma (HCC) diagnosis and treatment, with insights from his colleagues at Ochsner Health– Dr. Steven Young (hepatologist), Dr. Jonathan Mizrahi (medical oncologist), and Deondra Bonds-Adams (patient navigator).
43m